Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells
Liz J Valente, Brandon J Aubrey, Marco J Herold, Gemma L Kelly, Lina Happo, Clare L Scott, Andrea Newbold, Ricky W Johnstone, David CS Huang, Lyubomir T Vassilev, Andreas Strasser
CELL REPORTS | CELL PRESS | Published : 2016
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by Leukemia and Lymphoma Society (SCOR grant)
Awarded by Cancer Council Victoria
We thank Drs. J. M. Adams, A. Villunger, P. Bouillet, and S. Cory for gifts of mice; Drs. D. Segal, S. Glaser, and Y. Yao for human cancer cell lines; G. Siciliano and his colleagues for animal husbandry; E. Tsui and her colleagues for help with histology; S. Monard and his team for help with flow cytometry; Drs. S. Wilcox and A. Kueh for MiSeq runs and assistance with sample preparation; and Dr. L. Rohrbeck for the PUMA sgRNA and MiSeq primers. Work in the authors' laboratories was supported by the National Health and Medical Research Council (NHMRC) of Australia (program grant 1016701, project grants 1046010 and 637326, and fellowship # 1020363); the Leukemia and Lymphoma Society (SCOR grant #7413); the Cancer Council Victoria (post-graduate research fellowship to L.J.V.; project grant 1052309 to A.S.; Sir Edward Dunlop Fellowship in Cancer Research to C.L.S.); the Leukaemia Foundation National Research Program Clinical PhD Scholarship (to B.J.A.); and the Victorian Cancer Agency (clinical fellowship to C.L.S.). R.W.J. is a Principal Research Fellow of the NHMRC of Australia and supported by NHMRC program and project grants and by the Cancer Council Victoria. This work was made possible by operational infrastructure grants through the Australian Government (IRISS), the Victorian State Government (OIS), and the Australian Cancer Research Foundation.